Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 2:32 PM
Ignite Modification Date: 2025-12-25 @ 1:05 PM
NCT ID: NCT03852459
Description: TEAE was defined as an adverse event that was new or worsened in severity after the first dose of study drug.
Frequency Threshold: 5
Time Frame: Up to Day 7
Study: NCT03852459
Study Brief: Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Active Arm S-Ibuprofen Topical Gel 5% S-Ibuprofen: Topical Gel 5% 0 None 0 126 123 126 View
Placebo Arm Vehicle Topical Gel Vehicle: Vehicle Gel 0 None 0 125 117 125 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
application site erythema SYSTEMATIC_ASSESSMENT General disorders MedDRA (21.0) View
application site induration SYSTEMATIC_ASSESSMENT General disorders MedDRA (21.0) View
application site pain SYSTEMATIC_ASSESSMENT General disorders MedDRA (21.0) View
application site pruritus SYSTEMATIC_ASSESSMENT General disorders MedDRA (21.0) View
musculoskeletal stiffness SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (21.0) View
skin exfoliation SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (21.0) View